<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">Case studies have also indicated that pixantrone may be useful in the routine clinic setting, as a bridge to autologous SCT, or to induce a CR following relapse after allogenic SCT [
 <xref ref-type="bibr" rid="CR19">19</xref>, 
 <xref ref-type="bibr" rid="CR20">20</xref>]. One patient with DLBCL achieved a CR with third-line pixantrone monotherapy plus a single dose of rituximab and benefited from long-term remission after consolidation with high-dose chemotherapy and autologous SCT [
 <xref ref-type="bibr" rid="CR19">19</xref>]. Another patient with DLBCL who relapsed after allogeneic SCT achieved a CR with pixantrone without any considerable side effects [
 <xref ref-type="bibr" rid="CR20">20</xref>].
</p>
